Progyny (NASDAQ:PGNY) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Progyny (NASDAQ:PGNY) from a hold rating to a buy rating in a research report sent to investors on Saturday.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Canaccord Genuity Group decreased their price objective on Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Wednesday, March 11th. Citizens Jmp upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective for the company in a research note on Tuesday, January 20th. Citigroup upgraded Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Truist Financial decreased their price objective on Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and an average target price of $27.91.

Progyny Price Performance

Shares of Progyny stock opened at $18.12 on Friday. The business has a 50-day moving average of $18.48 and a 200 day moving average of $21.85. Progyny has a 12 month low of $16.10 and a 12 month high of $28.75. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 27.88, a price-to-earnings-growth ratio of 1.03 and a beta of 0.99.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. During the same period last year, the business posted $0.42 EPS. Progyny’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts anticipate that Progyny will post 0.6 earnings per share for the current year.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 7,455 shares of company stock worth $129,515. 9.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its position in shares of Progyny by 0.7% during the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after acquiring an additional 457 shares in the last quarter. Teza Capital Management LLC raised its position in shares of Progyny by 5.4% during the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after acquiring an additional 516 shares in the last quarter. Leibman Financial Services Inc. raised its position in shares of Progyny by 1.2% during the 4th quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock worth $1,192,000 after acquiring an additional 528 shares in the last quarter. Aristides Capital LLC raised its position in shares of Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after acquiring an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP raised its position in shares of Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after acquiring an additional 531 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.